Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

On April 27, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 3-7, 2022 in Chicago, Illinois (Press release, Galera Therapeutics, APR 27, 2022, View Source [SID1234613023]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation

Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC)
Abstract Number: 6005
Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics
Session Title: Head and Neck Cancer
Session Date and Time: Friday, June 3, 2022 | 2:45 p.m. – 5:45 p.m. CDT

Galera’s Phase 2 GRECO-2 study of rucosopasem (GC4711) in combination with stereotactic body radiation therapy in pancreatic cancer will also be presented at the ASCO (Free ASCO Whitepaper) meeting in a Trials in Progress poster session.

Poster Presentation

Title: GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer
Abstract Number: TPS4184
Presenter: Sarah Hoffe, M.D., H. Lee Moffitt Cancer Center
Session Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: Saturday, June 4, 2022 | 8:00 a.m. – 11:00 a.m. CDT

The titles of the abstracts are currently available in the ASCO (Free ASCO Whitepaper) digital program, with the full abstracts scheduled to be published on May 26, 2022, at 5 p.m. EDT.